IMARC Group, a leading market research company, has recently releases report titled "Drug Device Combination Products Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028". The study provides a detailed analysis of the industry, including the global drug-device combination products market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market. Report Highlights
How big is the drug-device combination products market?
The global drug-device combination products market size reached US$ 143.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 230.4 Billion by 2028, exhibiting a growth rate (CAGR) of 7.6% during 2023-2028.What are drug-device combination products?
Drug device combination products include medical devices and pharmaceutical ingredients that help deliver the drug to a preferred location in the patients body. They comprise drug-eluting stents, infusion pumps, inhalers, transdermal delivery systems, and prefilled syringes. They have minimal side effects and offer advantages like controlled drug administration and improved patient compliance. Request for a sample copy of this report: https://www.imarcgroup.com/drug-device-combination-products-market/requestsampleWhat are the growth prospects and trends in the drug-device combination products industry?
The growing prevalence of chronic diseases, such as asthma, cancer, diabetes, and cardiovascular disorders, represents one of the key factors driving the market. Moreover, rising preferences for smart and precision drug delivery systems, which minimize the amount of drug required for therapeutic efficacy, are driving the demand for drug device combination products across the globe. Besides this, several market players are introducing advanced technologies for tracking and monitoring different products. They are also expending on extensive research and development (RD) activities to develop next-generation products with high viscosity and formulations. Furthermore, the growing popularity of minimally invasive surgery (MIS) and portable devices like nebulizers and inhalers are other growth-inducing factors positively influencing the market.What is included in market segmentation?
The report has segmented the market into the following categories: Breakup by Product:- Drug Eluting Stents
- Transdermal Patches
- Infusion Pumps
- Drug Eluting Balloon
- Inhalers
- Others
- Cardiovascular
- Diabetes
- Cancer Treatment
- Respiratory Diseases
- Others
- Hospitals
- Ambulatory Surgical Centers
- Others
- North America (U.S. Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
- Latin America (Brazil, Mexico)
- Middle East Africa
Who are the key players operating in the industry?
The report covers the major market players including:- Abbott Laboratories
- Baxter International Inc.
- Bayer AG
- Becton Dickinson and Company
- Boston Scientific Corporation
- GlaxoSmithKline plc
- Johnson Johnson
- Medtronic plc
- Novartis AG
- Smith Nephew plc
- Stryker Corporation
- Terumo Corporation